Vertex casually drops Orkambi revenue slowdown, creating

Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.

S-1/A

S-1

S-1

S-1/A

ServiceNow Stock: Slowing Growth In Rising Rate Environment (NYSE:NOW)

technologies for profiling single cells to create an open-access

S-1

Oracle Stock (ORCL) Jumps After Revenue Tops Estimates on Strong Cloud Effort - Bloomberg

S-1

SEC Filing – Royalty Pharma

SEC Filing – Royalty Pharma

Vertex Reports First Quarter 2023 Financial Results

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

Dropbox Business Model - How Dropbox Makes Money?